The efficacy of ICI therapies, particularly with PD-1 monotherapies demonstrates considerable benefits, with response rates ranging from ~40% to 70% in specific cancer types such as melanoma, Merkel cell carcinoma, Hodgkin’s lymphoma, and tumors with high microsatellite instability (MSI) (112). This evidence concerns the gene PDCD1 and cancer.